PSA screening review finds fewer deaths, more diagnoses
The updated review found PSA screening likely reduces prostate cancer deaths, but evidence remains unclear for newer screening strategies combining PSA, kallikrein testing, and MRI.
Cochrane has updated its 2013 prostate cancer screening review, finding that PSA-based screening likely reduces prostate cancer-specific mortality. The review was published May 15 in the Cochrane Database of Systematic Reviews.
Reviewers analyzed 6 randomized trials involving 789,086 men in Canada, Europe, and the U.S. Participants were ages 45 to 80 and were followed for 3.2 to 23 years.
PSA testing likely reduced prostate cancer deaths over 23 years of follow-up, with 2 fewer deaths per 1,000 men screened, according to Cochrane. The mortality finding came from 1 study involving 162,241 men.
Screening also increased prostate cancer diagnoses. Cochrane reported 36 more prostate cancers and 34 more localized cancers per 1,000 men screened, while metastatic cancer diagnoses may have been reduced by 5 per 1,000 men screened.
Evidence on harms remained limited. Cochrane said the reviewed studies did not provide evidence on biopsy-related complications or treatment-related complications such as urinary, erectile, or bowel problems.
A newer screening strategy was assessed in 1 study involving 60,745 men. That approach combined PSA testing with a kallikrein panel and prostate imaging before biopsy.
Cochrane said the combined strategy likely finds more prostate cancers, but it remains unclear whether it reduces deaths from prostate cancer or any cause. The study did not report mortality outcomes.
The authors concluded that emerging alternatives such as kallikrein panel and MRI-based screening may have little to no effect on prostate cancer diagnoses, with mortality results not yet known.
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
Pediatric ED imaging gaps persist by race and insurance status
A cohort study of 857,034 pediatric ED visits found that stronger hospital pediatric capability was not associated with narrower imaging-use differences by race, ethnicity, or insurance status.
Chest X-ray AI study exposes lung cancer detection gaps
A head-to-head study of 7 commercial AI devices found sensitivity ranged from 20.8% to 77.8% for lung cancer detection on chest X-rays.
MRI radiomics score flags aggressive colorectal cancer subtype
The multicenter study found an MRI-based machine-learning radiomics score predicted CMS4 colorectal cancer and stratified recurrent metastasis risk.
Contrast tied to higher AKI risk in neonatal ICU study
The retrospective study found higher acute kidney injury rates in neonates exposed to iodinated contrast media, although most cases were stage 1.
Quantum BioPharma reports early PET tracer signal in MS study
The ongoing MGH study is evaluating [18F]3F4AP PET imaging for demyelinated neurons with intact axons in patients with multiple sclerosis.
Stage 4 breast cancer diagnoses rise over decade
A cohort study of 761,471 people found de novo stage 4 breast cancer incidence increased by 1.2% per year from 2010 to 2021.
SIR backs genicular artery embolization for knee osteoarthritis
The Society of Interventional Radiology issued a position statement supporting genicular artery embolization for symptomatic knee osteoarthritis.
Fluoride, lead co-exposure linked to lower youth BMD
Researchers analyzed NHANES data from 2,378 U.S. children and adolescents who underwent DEXA scans from 2013 to 2016.
Stanford receives $3.9M ARPA-H grant for MR lymphangiography
Stanford Medicine received up to $3.9M from ARPA-H to advance MR lymphangiography. Andreas Loening, MD, PhD, will lead work on faster scans, lymphatic-specific contrast agents, and contrast-free flow assessment.
Bayer PET tracer meets cardiac amyloidosis endpoints
Bayer reported positive topline phase 3 REVEAL results for I-124 evuzamitide, an investigational PET/CT radiotracer for suspected cardiac amyloidosis. The study met its sensitivity and specificity endpoints.
14-minute MRx scan maps 20+ brain biomarkers without contrast
University of Illinois researchers developed multiplexed MRI to map more than 20 brain biomarkers in a single scan using standard clinical MRI systems.
PSMA PET linked to more intensive prostate cancer treatment
A national claims analysis found that PSMA PET use was associated with higher initiation of androgen receptor pathway inhibitors and systemic therapy in newly diagnosed advanced prostate cancer.